{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:10:28Z","timestamp":1780535428699,"version":"3.54.1"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.3233\/jad-200378","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T13:24:53Z","timestamp":1591709093000},"page":"725-732","source":"Crossref","is-referenced-by-count":27,"title":["Effects of Citicoline as an Adjunct Treatment for Alzheimer\u2019s Disease: A Systematic Review"],"prefix":"10.1177","volume":"76","author":[{"given":"Bernadeth Lyn C.","family":"Piamonte","sequence":"first","affiliation":[{"name":"Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian I.","family":"Espiritu","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines"},{"name":"Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeda Michelle M.","family":"Anlacan","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines"},{"name":"Center for Memory and Cognition, Department of Neurosciences, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200378_ref1","volume-title":"World Alzheimer Report 2018. The state of the art of dementia research: New frontiers","author":"Patterson","year":"2018"},{"key":"10.3233\/JAD-200378_ref2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1192\/apt.bp.112.010462","article-title":"New diagnostic concepts in Alzheimer\u2019s disease","volume":"19","author":"Watkin","year":"2013","journal-title":"Adv Psychiatr Treat"},{"key":"10.3233\/JAD-200378_ref3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200378_ref4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jns.2012.07.003","article-title":"The ASCOMALVA trial: Association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer\u2019s disease with cerebrovascular injury: Interim results","volume":"322","author":"Amenta","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-200378_ref5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer\u2019s disease: Clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-200378_ref6","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease (Review)","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-200378_ref7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JAD-160808","article-title":"The Citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer\u2019s disease study","volume":"56","author":"Gareri","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200378_ref8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/jnc.12269","article-title":"Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke","volume":"126","author":"Hurtado","year":"2013","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-200378_ref9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/emmm.201302451","article-title":"SIRT1 and SIRT2: Emerging targets in neurodegeneration","volume":"5","author":"Donmez","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.3233\/JAD-200378_ref10","first-page":"131","article-title":"Effectiveness and safety of citicoline in mild vascular cognitive impairment: The IDEALE study","volume":"8","author":"Cotroneo","year":"2013","journal-title":"Clin Interv Aging"},{"key":"10.3233\/JAD-200378_ref11","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaborationb","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.3233\/JAD-200378_ref12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200378_ref13","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9781585629992","volume-title":"DSM-5\u00ae Handbook of Differential Diagnosis","author":"First","year":"2013"},{"key":"10.3233\/JAD-200378_ref14","unstructured":"The Ottawa Hospital Research Institute, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses."},{"key":"10.3233\/JAD-200378_ref15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40261-016-0454-3","article-title":"The CITIRIVAD Study: Citicoline plus rivastigmine in elderly patients affected with dementia study","volume":"36","author":"Castagna","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.3233\/JAD-200378_ref16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1358\/mf.1999.21.9.795632","article-title":"Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer\u2019s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion","volume":"21","author":"\u00c1lvarez","year":"1999","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.3233\/JAD-200378_ref17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: Targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"10.3233\/JAD-200378_ref18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mad.2005.09.017","article-title":"Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: An approach for enhancing cholinergic neurotransmission","volume":"127","author":"Amenta","year":"2006","journal-title":"Mech Ageing Dev"},{"key":"10.3233\/JAD-200378_ref19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jns.2009.02.349","article-title":"Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats","volume":"283","author":"Tayebati","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-200378_ref20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajcn\/87.2.424","article-title":"Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: The ATTICA study","volume":"87","author":"Detopoulou","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.3233\/JAD-200378_ref21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-200378_ref22","first-page":"1404","article-title":"Treatment of Alzheimer\u2019s disease","volume":"83","author":"Winslow","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.3233\/JAD-200378_ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002512-200522001-00002","article-title":"Guidelines for the treatment of Alzheimer\u2019s disease from the Italian association of psychogeriatrics","volume":"22","author":"Caltagirone","year":"2005","journal-title":"Drugs Aging"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:23Z","timestamp":1777370903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":23,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-200378","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}